Stock Events

Stock Events

Enanta Pharmaceuticals 

$13.54
0
+$0+0% Friday 05:54

Statistics

Day High
13.54
Day Low
13.54
52W High
-
52W Low
-
Volume
200
Avg. Volume
-
Mkt Cap
390.81M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

9FebExpected
Q3 2025
Next
-1.02
-0.94
-0.85
-0.77
Expected EPS
-0.767654
Actual EPS
N/A

Financials

-125.36%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
130.65MRevenue
-163.78MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ENTA.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences is a direct competitor in the antiviral drug market, particularly in treatments for hepatitis C, where Enanta and Gilead have had collaborations but also compete.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie competes with Enanta in the hepatitis C virus (HCV) treatment market, especially since Enanta has developed drugs that are part of AbbVie's HCV treatment regimens.
Merck
MRK
Mkt Cap214.76B
Merck & Co. is involved in developing treatments for infectious diseases, including hepatitis C, directly competing with Enanta's drug development focus.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals competes with Enanta in the development of treatments for cystic fibrosis, as both companies are involved in creating therapies for genetic and chronic diseases.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol Myers Squibb competes in the antiviral space, particularly in hepatitis B and C, areas where Enanta Pharmaceuticals has significant interest and development efforts.
Pfizer
PFE
Mkt Cap140.15B
Pfizer competes across a broad range of therapeutic areas, including antiviral drugs, which puts it in competition with Enanta Pharmaceuticals in the infectious disease market.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson, through its pharmaceutical division Janssen, competes with Enanta in the development of treatments for infectious diseases, including hepatitis C.
GSK
GSK
Mkt Cap94.51B
GlaxoSmithKline competes with Enanta in the development of vaccines and treatments for viral infections, including hepatitis and respiratory diseases.
Arrowhead Pharmaceuticals
ARWR
Mkt Cap5.86B
Arrowhead Pharmaceuticals is involved in developing RNAi therapeutics for chronic diseases, including hepatitis B, making it a competitor in the viral infection treatment market.

About

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
Show more...
CEO
Dr. Jay R. Luly Ph.D.
Employees
131
Country
US
ISIN
US29251M1062

Listings

F
DE
9EP.F
XNAS
US
ENTA
BOATS
BOATS
ENTA.BOATS

0 Comments

Share your thoughts

FAQ

What is Enanta Pharmaceuticals stock price today?▼
The current price of ENTA.BOATS is $13.54 USD — it has increased by +0% in the past 24 hours. Watch Enanta Pharmaceuticals stock price performance more closely on the chart.
What is Enanta Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Enanta Pharmaceuticals stocks are traded under the ticker ENTA.BOATS.
What is Enanta Pharmaceuticals market cap?▼
Today Enanta Pharmaceuticals has the market capitalization of 390.81M
When is the next Enanta Pharmaceuticals earnings date?▼
Enanta Pharmaceuticals is going to release the next earnings report on February 09, 2026.
What were Enanta Pharmaceuticals earnings last quarter?▼
ENTA.BOATS earnings for the last quarter are -0.87 USD per share, whereas the estimation was -1.02 USD resulting in a +14.83% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Enanta Pharmaceuticals revenue for the last year?▼
Enanta Pharmaceuticals revenue for the last year amounts to 130.65M USD.
What is Enanta Pharmaceuticals net income for the last year?▼
ENTA.BOATS net income for the last year is -163.78M USD.
How many employees does Enanta Pharmaceuticals have?▼
As of February 03, 2026, the company has 131 employees.
In which sector is Enanta Pharmaceuticals located?▼
Enanta Pharmaceuticals operates in the Health Care sector.
When did Enanta Pharmaceuticals complete a stock split?▼
Enanta Pharmaceuticals has not had any recent stock splits.
Where is Enanta Pharmaceuticals headquartered?▼
Enanta Pharmaceuticals is headquartered in Watertown, US.